Teva Pharmaceutical Industries (NYSE:TEVA) Given New $11.00 Price Target at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target boosted by UBS Group from $8.00 to $11.00 in a research report report published on Wednesday, Marketbeat.com reports. They currently have a neutral rating on the stock.

TEVA has been the topic of several other reports. Bank of America increased their target price on Teva Pharmaceutical Industries from $12.00 to $13.00 and gave the stock a buy rating in a research report on Friday, September 8th. StockNews.com assumed coverage on Teva Pharmaceutical Industries in a research report on Thursday, August 17th. They set a buy rating on the stock. Finally, Morgan Stanley assumed coverage on Teva Pharmaceutical Industries in a research report on Thursday, May 25th. They set an equal weight rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $10.88.

Teva Pharmaceutical Industries Stock Up 0.1 %

TEVA opened at $10.35 on Wednesday. The business’s fifty day moving average is $9.49 and its two-hundred day moving average is $8.66. The company has a debt-to-equity ratio of 2.43, a quick ratio of 0.67 and a current ratio of 1.02. The company has a market cap of $11.60 billion, a price-to-earnings ratio of -5.18, a PEG ratio of 1.41 and a beta of 1.17. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $11.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 27.93% and a negative net margin of 14.87%. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.69 billion. Analysts anticipate that Teva Pharmaceutical Industries will post 2.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 35,125 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $9.73, for a total transaction of $341,766.25. Following the completion of the sale, the chief financial officer now directly owns 99,162 shares in the company, valued at $964,846.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $8.30, for a total value of $437,758.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eliyahu Sharon Kalif sold 35,125 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $9.73, for a total value of $341,766.25. Following the completion of the sale, the chief financial officer now owns 99,162 shares of the company’s stock, valued at approximately $964,846.26. The disclosure for this sale can be found here. Insiders sold 89,848 shares of company stock worth $799,176 over the last three months. 0.62% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in Teva Pharmaceutical Industries by 5.5% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 19,315 shares of the company’s stock valued at $176,000 after purchasing an additional 1,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Teva Pharmaceutical Industries by 0.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 175,427 shares of the company’s stock worth $1,553,000 after buying an additional 1,100 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Teva Pharmaceutical Industries by 1.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 75,355 shares of the company’s stock worth $687,000 after buying an additional 1,266 shares during the last quarter. Marshall Wace LLP lifted its holdings in Teva Pharmaceutical Industries by 2.7% during the 4th quarter. Marshall Wace LLP now owns 48,771 shares of the company’s stock worth $445,000 after buying an additional 1,273 shares during the last quarter. Finally, Spire Wealth Management lifted its holdings in shares of Teva Pharmaceutical Industries by 32.7% in the 2nd quarter. Spire Wealth Management now owns 5,584 shares of the company’s stock worth $42,000 after purchasing an additional 1,375 shares during the last quarter. Hedge funds and other institutional investors own 43.23% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.